The US Food and Drug Administration (FDA) has approved Eli Lilly‘s osteoporosis drug Forteo [teriparatide (rDNA origin) injection] for patients with osteoporosis.

The drug is used to treat osteoporosis associated with sustained, systemic glucocorticoid therapy in men and women at high risk of fracture.

The FDA approval was based on a clinical study conducted by Lilly, which showed that in patients with glucocorticoid-induced osteoporosis, Forteo increased bone mineral density from baseline to 18 months of treatment by 7.2% at the lumbar spine, 3.6% at the total hip and 3.7% at the femoral neck.

Eli Lilly medical director Vladimir Kopernicky said that the FDA’s decision provides patients with a valuable treatment option for osteoporosis, which they may develop as a result of their sustained glucocorticoid use.